Nephrotoxicity in the Elderly Due to Co-Prescription of ACE Inhibitors and NSAIDs

Jolobe O.M.P. Evaluation of renal function in elderly heart failure patients on ACE inhibitors. Postgrad Med J 1998; 75: 275–7

Pitt B. , Zannad F. , Remme W. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341: 709–17

Berry C. , McMurray J.J.V. Serious adverse events experienced by patients with chronic heart failure taking spironolactone. Heart 2001; 85: e8

Schepkens H. , Vanholder R. , Billiouw J-M , Lamiere N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001; 110: 438–41

Tan S.Y. , Shapiro R. , Franco R. Indomethacin-induced prostaglandin inhibition with hyperkalemia: a reversible cause of hyporeninemic hypoaldosteronism. Ann Intern Med 1979; 90: 783–5

Wolf G. , Porth J. , Stahl R.A.K. Acute renal failure with rofecoxib. Ann Intern Med 2000; 133: 394

Parazella M.A. , Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal anti-inflammatory drugs. Am J Med 2001; 111: 64–6